<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Drug eluting stent</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Elixir’s Dynamx bioadaptor meets primary endpoint</title>
      <description>
        <![CDATA[Elixir Medical Corp. reported positive 12-month data from the Infinity-Swedeheart trial that compared its Dynamx coronary bioadaptor system to Medtronic plc’s Resolute Onyx zotarolimus drug-eluting stent in patients requiring percutaneous coronary intervention with coronary artery disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711951</guid>
      <pubDate>Thu, 05 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711951-elixirs-dynamx-bioadaptor-meets-primary-endpoint</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Dynamx-coronary-bioadaptor-system-5sept24.webp?t=1725572917" type="image/jpeg" medium="image" fileSize="212722">
        <media:title type="plain">Dynamx coronary bioadaptor system</media:title>
        <media:description type="plain">Dynamx coronary bioadaptor system. Credit: Dynamx</media:description>
      </media:content>
    </item>
    <item>
      <title>Data shows Elixir’s coronary implant with TRx coating is safe</title>
      <description>
        <![CDATA[Elixir Medical Corp. reported positive 12-month clinical data from the Desyne BDS Plus randomized controlled trial which evaluated its Desyne BDS plus system, a triple drug-eluting coronary implant with site-specific antithrombotic therapeutic coating, against a contemporary, durable polymer drug-eluting stent in the treatment of de novo native coronary artery lesions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708562</guid>
      <pubDate>Tue, 21 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708562-data-shows-elixirs-coronary-implant-with-trx-coating-is-safe</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Thrombosis-blood-clot.webp?t=1676651893" type="image/png" medium="image" fileSize="1702000">
        <media:title type="plain">Illustration of clot forming in blood vessel</media:title>
      </media:content>
    </item>
    <item>
      <title>Sino Medical’s drug eluting stent approved for vascular stenosis in China</title>
      <description>
        <![CDATA[Sino Medical Sciences Technology Inc. received marketing approval from China’s NMPA for its drug eluting stent system to improve vascular stenosis in patients with localized ischemic heart disease. The product is designed to improve the speed of wound healing and accelerate the recovery of vascular endothelium after stent implantation. It fits vessels with a diameter of 2.25 mm to 4.00 mm and a lesion length of less than or equal to 40 mm.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690732</guid>
      <pubDate>Tue, 18 Oct 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690732-sino-medicals-drug-eluting-stent-approved-for-vascular-stenosis-in-china</link>
    </item>
    <item>
      <title>Medtronic touts data for Resolute Onyx, Picardia data indicates TAVR shortcut</title>
      <description>
        <![CDATA[Following last week’s FDA approval of its Onyx Frontier drug eluting stent (DES), Medtronic plc released results at EuroPCR from a real-world, multicenter prospective study using its Resolute Onyx platform for percutaneous coronary interventions (PCI) in the left main artery. Rehovot, Israel-based Pi-Cardia Ltd. also released early data for patients treated with its Short Cut transcatheter device for coronary obstruction prevention.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519036</guid>
      <pubDate>Fri, 20 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519036-medtronic-touts-data-for-resolute-onyx-picardia-data-indicates-tavr-shortcut</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/Europcr-main-stage.webp?t=1653082112" type="image/png" medium="image" fileSize="926188">
        <media:title type="plain">Presentation on the EuroPCR 2022 main stage</media:title>
        <media:description type="plain">EuroPCR meeting in Paris
</media:description>
      </media:content>
    </item>
    <item>
      <title>Stents, FFR software take a hit in study comparing PCI with coronary artery bypass</title>
      <description>
        <![CDATA[Despite the morbidity associated with coronary artery bypass graft, this procedure has never been entirely displaced by percutaneous coronary intervention. The results from the latest in a series of studies does not seem to help the case for drug-eluting stents (DES) for patients with three-vessel disease, as the data from this study failed to demonstrate non-inferiority for DES devices implanted with the help of fractional flow reserve measurement to ensure optimal stent placement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513044</guid>
      <pubDate>Thu, 04 Nov 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/513044-stents-ffr-software-take-a-hit-in-study-comparing-pci-with-coronary-artery-bypass</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cross-section-valves.webp?t=1626905884" type="image/png" medium="image" fileSize="922624">
        <media:title type="plain">3D illustration of heart cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>New study of paclitaxel devices reverses narrative regarding mortality</title>
      <description>
        <![CDATA[The controversy over the use of paclitaxel in devices for the peripheral vasculature has taken a significant bite out of sales, but a new study serves to help reverse the narrative regarding mortality. According to a study of more than 168,000 Medicare patients, stents and angioplasty balloons coated with paclitaxel (PTX) were non-inferior to non-coated devices for mortality out to nearly three years, a finding that may encourage clinicians to return to normal utilization patterns and thus help to restore sales volumes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/508253</guid>
      <pubDate>Tue, 15 Jun 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508253-new-study-of-paclitaxel-devices-reverses-narrative-regarding-mortality</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cardiovascular-stent-drug-eluting-device.webp?t=1623790472" type="image/png" medium="image" fileSize="1574468">
        <media:title type="plain">Illustration of stent angioplasty balloon in artery</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA greenlights Synergy Megatron for large proximal vessels</title>
      <description>
        <![CDATA[Boston Scientific Corp. has received the U.S. FDA&rsquo;s nod for its Synergy Megatron drug-eluting stent (DES) system. The company said the premarket approval makes Synergy Megatron the first platform in the U.S. that is designed for large, proximal vessels. The Synergy Megatron biopolymer (BP) stent is indicated &ldquo;for improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease, stable or unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in native coronary arteries.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503011</guid>
      <pubDate>Fri, 29 Jan 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503011-fda-greenlights-synergy-megatron-for-large-proximal-vessels</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/01-29-Boston-Sci-Synergy-Megatron.webp?t=1611957932" type="image/png" medium="image" fileSize="649351">
        <media:title type="plain">Device image</media:title>
        <media:description type="plain">Synergy Megatron drug-eluting stent. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>New data take another bite out of Katsansos, but registries now more topical</title>
      <description>
        <![CDATA[The storm of controversy over the use of paclitaxel in devices for the peripheral vasculature had a dramatic effect on utilization, but a new study coming out of Sweden seems to have helped further ease concerns about purported mortality associated with this antiproliferative. While this unplanned interim analysis lends yet more support to the view that the mortality signal in the so-called Katsanos paper did not reflect a true biological finding, the net effect of the controversy has prompted a call for a registry that might eliminate some statistical noise that had a significant and harmful impact on patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/502731</guid>
      <pubDate>Fri, 22 Jan 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/502731-new-data-take-another-bite-out-of-katsansos-but-registries-now-more-topical</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiovascular-legs-BTK.webp?t=1603146899" type="image/png" medium="image" fileSize="752101">
        <media:title type="plain">Illustration of vascular system in the legs</media:title>
      </media:content>
    </item>
    <item>
      <title>PICCOLETO II study resurrects balloon vs. stent debate for small coronary arteries</title>
      <description>
        <![CDATA[The drug-eluting balloon (DEB) has not displaced the drug-eluting stent (DES) for treatment of infarcts, but that may be changing with the results of the PICCOLETO II study. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/500809</guid>
      <pubDate>Tue, 01 Dec 2020 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/500809-piccoleto-ii-study-resurrects-balloon-vs-stent-debate-for-small-coronary-arteries</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/PAD-artery-plaque.webp?t=1588379965" type="image/png" medium="image" fileSize="468867">
        <media:title type="plain">Artery and plaque</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic gets FDA nod for expanded labeling with Resolute Onyx DES</title>
      <description>
        <![CDATA[Medtronic plc&rsquo;s winning streak continued this week with the announcement that the U.S. FDA had given its nod for new one-month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx drug-eluting stent (DES). The approval is based on results from the Onyx ONE Clear Study that evaluated about 1,500 complex HBR patients on one-month DAPT treated with Resolute Onyx.]]>
      </description>
      <guid>http://www.bioworld.com/articles/498520</guid>
      <pubDate>Fri, 02 Oct 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/498520-medtronic-gets-fda-nod-for-expanded-labeling-with-resolute-onyx-des</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/10-2-Medtronic-Resolute-Onyx.webp?t=1601674851" type="image/png" medium="image" fileSize="410206">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Resolute Onyx drug-eluting stent. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives thumbs up to Synergy for HBR indication</title>
      <description>
        <![CDATA[Boston Scientific Corp. has received the U.S. FDA’s nod for a high bleeding risk (HBR) indication for the Synergy drug-eluting stent system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/496689</guid>
      <pubDate>Wed, 12 Aug 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496689-fda-gives-thumbs-up-to-synergy-for-hbr-indication</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/8-12-Boston-Scientific-SYNERGY.webp?t=1597265097" type="image/png" medium="image" fileSize="436035">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Synergy drug-eluting stent system. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Elixir Medical sees positive data for adaptive remodeling coronary stent technology</title>
      <description>
        <![CDATA[Elixir Medical Corp., reported positive 12-month results for its Dynamx Coronary Bioadaptor System, with no target vessel revascularization (TVR) or stent thrombosis and adaptive remodeling of the artery to sustain healthy blood flow. The findings, from a multisite European trial, were presented during a late-breaking trials session at the PCR e-Course virtual meeting in Paris.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436085</guid>
      <pubDate>Mon, 29 Jun 2020 11:30:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436085-elixir-medical-sees-positive-data-for-adaptive-remodeling-coronary-stent-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-26-Elixir-DynamX.webp?t=1593204401" type="image/png" medium="image" fileSize="948325">
        <media:title type="plain">Illustration of device in artery</media:title>
        <media:description type="plain">Dynamx Coronary Bioadaptor system. Credit: Elixir Medical Corp. </media:description>
      </media:content>
    </item>
    <item>
      <title>Data underscores benefits of Biotronik’s ultrathin strut Orsiro DES</title>
      <description>
        <![CDATA[NATIONAL HARBOR, Md. &ndash; Berlin-based Biotronik SE &amp; Co. reported new data from the BIOFLOW-V trial showing that its Orsiro ultrathin strut drug-eluting stent (DES) continued to outperform Abbott Laboratories&rsquo; Xience DES through three years&rsquo; follow-up. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/433304</guid>
      <pubDate>Tue, 25 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433304-data-underscores-benefits-of-biotroniks-ultrathin-strut-orsiro-des</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/2-25-Biotronik-Orsiro.webp?t=1582669265" type="image/png" medium="image" fileSize="496855">
        <media:title type="plain">2-25-Biotronik-Orsiro.png</media:title>
        <media:description type="plain">Orsiro. Credit: Biotronik Inc. </media:description>
      </media:content>
    </item>
    <item>
      <title>Biodegradable polymer stents show well in study against durable polymers</title>
      <description>
        <![CDATA[While the disappearing drug-eluting stent seems to have faded from view for the time being, several manufacturers have invested in fabrication of drug-eluting stents with polymers that absorb once the drug of elution has done its work. A new study indicates that patients who have already had a myocardial infarction fare better on stents made with these biodegradable polymers, an outcome that may soon push second-generation DES devices into med-tech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432248</guid>
      <pubDate>Tue, 07 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432248-biodegradable-polymer-stents-show-well-in-study-against-durable-polymers</link>
    </item>
    <item>
      <title>Meta-analysis lends little support to paclitaxel mortality theory</title>
      <description>
        <![CDATA[The controversy over paclitaxel (PCT)-associated mortality in devices for the peripheral arteries is far from over, but another medical journal article has punched a hole in the credibility of the paclitaxel theory with the conclusion that the evidence is unequivocal and may be unpersuasive to physicians.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432144</guid>
      <pubDate>Thu, 02 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432144-meta-analysis-lends-little-support-to-paclitaxel-mortality-theory</link>
    </item>
    <item>
      <title>Study bolsters case for stenting over bypass in long femoropopliteal lesions</title>
      <description>
        <![CDATA[The recent controversy over the use of paclitaxel in the peripheral vasculature has clouded the larger debate over whether bypass is superior to endovascular therapies for the lower limbs. However, a new study suggests that nitinol stents provide a feasible alternative to bypass even for lesions of the femoropopliteal artery that are 30 cm in length. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/431449</guid>
      <pubDate>Wed, 27 Nov 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431449-study-bolsters-case-for-stenting-over-bypass-in-long-femoropopliteal-lesions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/PAD-artery-plaque.webp?t=1588379965" type="image/png" medium="image" fileSize="468867">
        <media:title type="plain">Artery and plaque</media:title>
      </media:content>
    </item>
    <item>
      <title>Analysis appears to take some of the heat off paclitaxel-eluting stents, DCBs</title>
      <description>
        <![CDATA[LONDON – There is no evidence for increased mortality in patients receiving paclitaxel-eluting stents and drug-coated balloons (DCBs) to treat peripheral arterial disease, according to the largest real-world safety analysis to date. The findings may come as a relief to many, particularly after a meta-analysis published in December 2018 led to safety warnings and restrictions on the use of coated and drug-eluting devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430441</guid>
      <pubDate>Thu, 10 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430441-analysis-appears-to-take-some-of-the-heat-off-paclitaxel-eluting-stents-dcbs</link>
    </item>
  </channel>
</rss>
